407 related articles for article (PubMed ID: 21038414)
1. Conjugation is essential for the anticholestatic effect of NorUrsodeoxycholic acid in taurolithocholic acid-induced cholestasis in rat liver.
Denk GU; Maitz S; Wimmer R; Rust C; Invernizzi P; Ferdinandusse S; Kulik W; Fuchsbichler A; Fickert P; Trauner M; Hofmann AF; Beuers U
Hepatology; 2010 Nov; 52(5):1758-68. PubMed ID: 21038414
[TBL] [Abstract][Full Text] [Related]
2. Tauroursodeoxycholic acid exerts anticholestatic effects by a cooperative cPKC alpha-/PKA-dependent mechanism in rat liver.
Wimmer R; Hohenester S; Pusl T; Denk GU; Rust C; Beuers U
Gut; 2008 Oct; 57(10):1448-54. PubMed ID: 18583398
[TBL] [Abstract][Full Text] [Related]
3. Tauroursodeoxycholic acid inserts the apical conjugate export pump, Mrp2, into canalicular membranes and stimulates organic anion secretion by protein kinase C-dependent mechanisms in cholestatic rat liver.
Beuers U; Bilzer M; Chittattu A; Kullak-Ublick GA; Keppler D; Paumgartner G; Dombrowski F
Hepatology; 2001 May; 33(5):1206-16. PubMed ID: 11343250
[TBL] [Abstract][Full Text] [Related]
4. Tauroursodeoxycholic acid reduces bile acid-induced apoptosis by modulation of AP-1.
Pusl T; Vennegeerts T; Wimmer R; Denk GU; Beuers U; Rust C
Biochem Biophys Res Commun; 2008 Feb; 367(1):208-12. PubMed ID: 18164257
[TBL] [Abstract][Full Text] [Related]
5. Role of mitogen-activated protein kinases in tauroursodeoxycholic acid-induced bile formation in cholestatic rat liver.
Denk GU; Hohenester S; Wimmer R; Böhland C; Rust C; Beuers U
Hepatol Res; 2008 Jul; 38(7):717-26. PubMed ID: 18328068
[TBL] [Abstract][Full Text] [Related]
6. Taurolithocholic acid exerts cholestatic effects via phosphatidylinositol 3-kinase-dependent mechanisms in perfused rat livers and rat hepatocyte couplets.
Beuers U; Denk GU; Soroka CJ; Wimmer R; Rust C; Paumgartner G; Boyer JL
J Biol Chem; 2003 May; 278(20):17810-8. PubMed ID: 12626520
[TBL] [Abstract][Full Text] [Related]
7. 24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice.
Fickert P; Wagner M; Marschall HU; Fuchsbichler A; Zollner G; Tsybrovskyy O; Zatloukal K; Liu J; Waalkes MP; Cover C; Denk H; Hofmann AF; Jaeschke H; Trauner M
Gastroenterology; 2006 Feb; 130(2):465-81. PubMed ID: 16472600
[TBL] [Abstract][Full Text] [Related]
8. Different protective effects of tauroursodeoxycholate, ursodeoxycholate, and 23-methyl-ursodeoxycholate against taurolithocholate-induced cholestasis.
Baumgartner U; Schölmerich J; Sellinger M; Reinhardt M; Ruf G; Farthmann EH
Dig Dis Sci; 1996 Feb; 41(2):250-5. PubMed ID: 8601366
[TBL] [Abstract][Full Text] [Related]
9. Characterization of ursodeoxycholic and norursodeoxycholic acid as substrates of the hepatic uptake transporters OATP1B1, OATP1B3, OATP2B1 and NTCP.
König J; Klatt S; Dilger K; Fromm MF
Basic Clin Pharmacol Toxicol; 2012 Aug; 111(2):81-6. PubMed ID: 22333292
[TBL] [Abstract][Full Text] [Related]
10. Differential effects of norUDCA and UDCA in obstructive cholestasis in mice.
Fickert P; Pollheimer MJ; Silbert D; Moustafa T; Halilbasic E; Krones E; Durchschein F; Thüringer A; Zollner G; Denk H; Trauner M
J Hepatol; 2013 Jun; 58(6):1201-8. PubMed ID: 23369794
[TBL] [Abstract][Full Text] [Related]
11. Drug insight: Mechanisms and sites of action of ursodeoxycholic acid in cholestasis.
Beuers U
Nat Clin Pract Gastroenterol Hepatol; 2006 Jun; 3(6):318-28. PubMed ID: 16741551
[TBL] [Abstract][Full Text] [Related]
12. Tauroursodeoxycholic acid inserts the bile salt export pump into canalicular membranes of cholestatic rat liver.
Dombrowski F; Stieger B; Beuers U
Lab Invest; 2006 Feb; 86(2):166-74. PubMed ID: 16344857
[TBL] [Abstract][Full Text] [Related]
13. Ursodeoxycholate and tauroursodeoxycholate inhibit cholangiocyte growth and secretion of BDL rats through activation of PKC alpha.
Alpini G; Baiocchi L; Glaser S; Ueno Y; Marzioni M; Francis H; Phinizy JL; Angelico M; Lesage G
Hepatology; 2002 May; 35(5):1041-52. PubMed ID: 11981754
[TBL] [Abstract][Full Text] [Related]
14. Side chain structure determines unique physiologic and therapeutic properties of norursodeoxycholic acid in Mdr2-/- mice.
Halilbasic E; Fiorotto R; Fickert P; Marschall HU; Moustafa T; Spirli C; Fuchsbichler A; Gumhold J; Silbert D; Zatloukal K; Langner C; Maitra U; Denk H; Hofmann AF; Strazzabosco M; Trauner M
Hepatology; 2009 Jun; 49(6):1972-81. PubMed ID: 19475687
[TBL] [Abstract][Full Text] [Related]
15. Novel biotransformation and physiological properties of norursodeoxycholic acid in humans.
Hofmann AF; Zakko SF; Lira M; Clerici C; Hagey LR; Lambert KK; Steinbach JH; Schteingart CD; Olinga P; Groothuis GM
Hepatology; 2005 Dec; 42(6):1391-8. PubMed ID: 16317695
[TBL] [Abstract][Full Text] [Related]
16. Anticholestatic mechanisms of ursodeoxycholic acid in lipopolysaccharide-induced cholestasis.
Razori MV; Maidagan PM; Ciriaci N; Andermatten RB; Barosso IR; Martín PL; Basiglio CL; Sánchez Pozzi EJ; Ruiz ML; Roma MG
Biochem Pharmacol; 2019 Oct; 168():48-56. PubMed ID: 31202734
[TBL] [Abstract][Full Text] [Related]
17. Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited.
Paumgartner G; Beuers U
Hepatology; 2002 Sep; 36(3):525-31. PubMed ID: 12198643
[TBL] [Abstract][Full Text] [Related]
18. Lessons from the toxic bile concept for the pathogenesis and treatment of cholestatic liver diseases.
Trauner M; Fickert P; Halilbasic E; Moustafa T
Wien Med Wochenschr; 2008; 158(19-20):542-8. PubMed ID: 18998069
[TBL] [Abstract][Full Text] [Related]
19. norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis.
Fickert P; Hirschfield GM; Denk G; Marschall HU; Altorjay I; Färkkilä M; Schramm C; Spengler U; Chapman R; Bergquist A; Schrumpf E; Nevens F; Trivedi P; Reiter FP; Tornai I; Halilbasic E; Greinwald R; Pröls M; Manns MP; Trauner M;
J Hepatol; 2017 Sep; 67(3):549-558. PubMed ID: 28529147
[TBL] [Abstract][Full Text] [Related]
20. All-trans-retinoic acid improves cholestasis in α-naphthylisothiocyanate-treated rats and Mdr2-/- mice.
Cai SY; Mennone A; Soroka CJ; Boyer JL
J Pharmacol Exp Ther; 2014 Apr; 349(1):94-8. PubMed ID: 24492652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]